2-AIN-506 a 2-AIN-252: Seminár z bioinformatiky (2) a (4)
Leto 2021

Mark S. Graham et al.. The effect of SARS-CoV-2 variant B.1.1.7 on symptomatology, re-infection and transmissibility. Technical Report 10.1101/2021.01.28.21250680, medRxiv,

Download preprint: not available

Download from publisher: https://doi.org/10.1101/2021.01.28.21250680

Related web page: not available

Bibliography entry: BibTeX


The new SARS-CoV-2 variant B.1.1.7 was identified in December 2020 in the 
South-East of England, and rapidly increased in frequency and geographic 
spread. While there is some evidence for increased transmissibility of 
this variant, it is not known if the new variant presents with variation 
in symptoms or disease course, or if previously infected individuals may 
become reinfected with the new variant. Using longitudinal symptom and 
test reports of 36,920 users of the Covid Symptom Study app testing 
positive for COVID-19 between 28 September and 27 December 2020, we 
examined the association between the regional proportion of B.1.1.7 and 
reported symptoms, disease course, rates of reinfection, and 
transmissibility. We found no evidence for changes in reported symptoms, 
disease severity and disease duration associated with B.1.1.7. We found a 
likely reinfection rate of around 0.7% (95% CI 0.6-0.8), but no evidence 
that this was higher compared to older strains. We found an increase in 
R(t) by a factor of 1.35 (95% CI 1.02-1.69). Despite this, we found that 
regional and national lockdowns have reduced R(t) below 1 in regions with 
very high proportions of B.1.1.7.